marked.bio

RAS inhibitor · small molecule

GFH276

4 active trials across 2 of our biomarkers, targeting RAS. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
KRAS G12D 4 4 Phase 2
KRAS G12C 3 3 Phase 1/2

Sponsors

Industry sponsors leading active biomarker-selected trials of GFH276.

  1. Genfleet Therapeutics 4

Trials

4 of 4 trials shown

  1. This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.

    Not yet recruiting Phase 1/2 Genfleet Therapeutics Started 2026Primary completion 2027-12 NCT07846358

    GFH276tislelizumabpemetrexedcisplatincarboplatin

    Confirmed RAS mutation or KRAS amplification；tumor cell PD L1 test report available

    KRAS G12CKRAS G12DRAS Mutation, Non-small Cell Lung Cancer (NSCLC)

  2. A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

    Recruiting Phase 1/2 Genfleet Therapeutics Started 2026Primary completion 2027-11 NCT07678593

    GFH276cetuximabnab-paclitaxelgemcitabinefluorouracilleucovorinirinotecanoxaliplatin

    …cally or cytologically confirmed locally advanced or metastatic solid tumor and PDAC with RAS mutation or KRAS amplification

    KRAS G12CKRAS G12DAdvanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma, RAS Mutation

  3. A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation

    Recruiting Phase 2 Genfleet Therapeutics Started 2026Primary completion 2028-08 NCT07784374

    VS-7375GFH276GFS202A

    …reviously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation

    KRAS G12DPancreatic Cancer

  4. A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors

    Not yet recruiting Phase 1/2 Genfleet Therapeutics Started 2025Primary completion 2027-09 NCT07198321

    GFH276

    … Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors

    KRAS G12CKRAS G12DCancer, PDAC, CRC (Colorectal Cancer), NSCLC